Prothena reports Q2 net loss of $18.6M, revenue $1.0M; updates cash guidance to ~$259M

PROTHENA CORP PUBLIC LTD CO

Net loss of $18.6M in Q2 2026 vs $125.8M loss in Q2 2025; basic EPS loss $0.36 vs $2.34.
Total revenue $1.0M in Q2, $52.1M in H1 2026 (includes $50M Novo Nordisk milestone).
Cash and restricted cash $289.1M at June 30, 2026; no debt.
Updated FY 2026 year-end cash guidance to ~$259M (midpoint), down $14M from prior due to share repurchases.
Repurchased 2,243,888 shares in H1 2026 for $22.3M under $100M program; $55M milestone from BMS possible by YE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.